Clinical trial · Observational
Gemcitabine in NK/T Cell Lymphoma
Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma
NCT01660568CI-TRIAL-00009449completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NK/T Cell Lymphoma | Nasal Type Extranodal NK/T-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- relapsed or refractory NK/T cell lymphoma with gemcitabine
Primary outcomes (1)
- measure
- Overall response rate
- timeFrame
- 2012-May
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * NK/T cell lymphoma * relapse or refractory disease * gemcitabine containing treatment Exclusion Criteria:
References
Publications (0)
Data not yet available
No reference posted for this study.